HFA 23: REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy

We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4.
REDWOOD-HCM Cohort 4 assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that aficamten treatment was well-tolerated in patients with nHCM, supporting further study of the drug in a phase 3 trial.
Interview Questions:
-What is currently understood about the pathophysiology of nHCM and what treatment options are available in 2023?
-How does Aficamten, a selective inhibitor of cardiac myosin, work?
-What was the study design, patient population, and outcome measures of REDWOOD-HCM-Cohort 4?
-What data was presented at the HFA and what conclusions can be drawn from the findings?
-What safety considerations and adverse events were observed?
-What are the next steps in research or clinical development?
Visit Radcliffe Cardiology: www.radcliffecardiology.com/?...
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on Twitter: / radcliffecardio

[@drzavahercegbosnaponosna5974]

Could Aficamten be effective in treating my LVH and distolic dysfunction I/IV?